Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CRYO CELL INTERNATIONAL INCCCEL · Entity 7400 | VP Finance, CFO | May 28, 2026 | May 29, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CRYO CELL INTERNATIONAL INC
Report date May 28, 2026 · Filed May 29, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 52,896 |
Reported balance
After 2026-05-28 transaction · row 1
1 source rowRow 1 · 2026-05-28 · Exercise / conversion · Acquired 7,500 · Balance 52,896 |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $3.10 · Expires 2026-06-02 | Direct | 0 |
Reported balance
After 2026-05-28 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-05-28 · Exercise / conversion · Disposed 7,500 · Balance 0 |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $8.00 · Expires 2027-09-23 | Direct | 7,000 |
Reported balance
Holding disclosure · report date 2026-05-28 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance 7,000 F1: Stock options vest 1/5 per year commencing on September 23, 2020. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $4.62 · Expires 2028-01-13 | Direct | 20,000 |
Reported balance
Holding disclosure · report date 2026-05-28 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance 20,000 |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $5.88 · Expires 2028-12-22 | Direct | 10,000 |
Reported balance
Holding disclosure · report date 2026-05-28 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance 10,000 F2: Stock options vest 1/3 upon issuance, 1/3 on December 22, 2024 and 1/3 on December 22, 2025. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $7.35 · Expires 2030-01-21 | Direct | 10,000 |
Reported balance
Holding disclosure · report date 2026-05-28 · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · Balance 10,000 F3: Stock options vest 1/3 upon issuance, 1/3 on January 22, 2026 and 1/3 on January 22, 2027. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $3.54 · Expires 2031-01-07 | Direct | 10,000 |
Reported balance
Holding disclosure · report date 2026-05-28 · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · Balance 10,000 F4: Stock options vest 1/3 upon issuance, 1/3 on January 7, 2027 and 1/3 on January 7, 2028. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $3.54 · Expires 2031-01-07 | Direct | 20,000 |
Reported balance
Holding disclosure · report date 2026-05-28 · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · Balance 20,000 F5: The stock options were granted pursuant to the Cryo-Cell 2022 Stock Incentive Plan and an individual award agreement. The options are divided into three equal tranches, each subject to both time-based vesting and stock-price performance conditions. One tranche vests after the first anniversary of the grant date and upon the Company's common stock achieving an average closing price of at least $6 per share over 20 consecutive trading days. One tranche vests after the second anniversary and upon achieving an average closing price of at least $8 per share over 20 consecutive trading days. One tranche vests after the third anniversary and upon achieving an average closing price of at least $10 per share over 20 consecutive trading days, in each case subject to the reporting person's continued service to the Company. |
Filing footnotes · ownership attribution and instrument terms
F1: Stock options vest 1/5 per year commencing on September 23, 2020.
F2: Stock options vest 1/3 upon issuance, 1/3 on December 22, 2024 and 1/3 on December 22, 2025.
F3: Stock options vest 1/3 upon issuance, 1/3 on January 22, 2026 and 1/3 on January 22, 2027.
F4: Stock options vest 1/3 upon issuance, 1/3 on January 7, 2027 and 1/3 on January 7, 2028.
F5: The stock options were granted pursuant to the Cryo-Cell 2022 Stock Incentive Plan and an individual award agreement. The options are divided into three equal tranches, each subject to both time-based vesting and stock-price performance conditions. One tranche vests after the first anniversary of the grant date and upon the Company's common stock achieving an average closing price of at least $6 per share over 20 consecutive trading days. One tranche vests after the second anniversary and upon achieving an average closing price of at least $8 per share over 20 consecutive trading days. One tranche vests after the third anniversary and upon achieving an average closing price of at least $10 per share over 20 consecutive trading days, in each case subject to the reporting person's continued service to the Company.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 28, 2026 Filed May 29, 2026 20:30 UTC | CRYO CELL INTERNATIONAL INC CCEL · Entity 7400 | Exercise / conversionStock Option · Derivative | 7,500 | $3.10 Strike: $3.10 | $23,250.00 |
DisclosureSEC source: 0001193125-26-248432 · ownership.xml · derivative · entry 8 TAYMANS JILL M · CIK 0001261283 · VP Finance, CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,500 shares Expires 2026-06-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 28, 2026 Filed May 29, 2026 20:30 UTC | CRYO CELL INTERNATIONAL INC CCEL · Entity 7400 | Exercise / conversionCommon Stock | 7,500 | $3.10 | $23,250.00 |
DisclosureSEC source: 0001193125-26-248432 · ownership.xml · nonDerivative · entry 1 TAYMANS JILL M · CIK 0001261283 · VP Finance, CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,896 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 07, 2026 Filed Jan 9, 2026 22:00 UTC | CRYO CELL INTERNATIONAL INC CCEL · Entity 7400 | GrantStock Option · Derivative | 20,000 | $3.54 Strike: $3.54 | $70,800.00 |
DisclosureSEC source: 0001193125-26-009067 · ownership.xml · derivative · entry 8 TAYMANS JILL M · CIK 0001261283 · VP Finance, CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2031-01-07 F5 · derivative.exercise_date: The stock options were granted pursuant to the Cryo-Cell 2022 Stock Incentive Plan and an individual award agreement. The options are divided into three equal tranches, each subject to both time-based vesting and stock-price performance conditions. One tranche vests after the first anniversary of the grant date and upon the Company's common stock achieving an average closing price of at least $6 per share over 20 consecutive trading days. One tranche vests after the second anniversary and upon achieving an average closing price of at least $8 per share over 20 consecutive trading days. One tranche vests after the third anniversary and upon achieving an average closing price of at least $10 per share over 20 consecutive trading days, in each case subject to the reporting person's continued service to the Company. Read SEC document |
| January 07, 2026 Filed Jan 9, 2026 22:00 UTC | CRYO CELL INTERNATIONAL INC CCEL · Entity 7400 | GrantStock Option · Derivative | 10,000 | $3.54 Strike: $3.54 | $35,400.00 |
DisclosureSEC source: 0001193125-26-009067 · ownership.xml · derivative · entry 7 TAYMANS JILL M · CIK 0001261283 · VP Finance, CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2031-01-07 F4 · derivative.exercise_date: Stock options vest 1/3 upon issuance, 1/3 on January 7, 2027 and 1/3 on January 7, 2028. Read SEC document |
| January 21, 2025 Filed Jan 23, 2025 22:00 UTC | CRYO CELL INTERNATIONAL INC CCEL · Entity 7400 | GrantStock Option · Derivative | 10,000 | $7.35 Strike: $7.35 | $73,500.00 |
DisclosureSEC source: 0000950170-25-008393 · ownership.xml · derivative · entry 6 TAYMANS JILL M · CIK 0001261283 · VP Finance, CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2030-01-21 F3 · derivative.exercise_date: Stock options vest 1/3 upon issuance, 1/3 on January 21, 2026 and 1/3 on January 21, 2027. Read SEC document |
| December 22, 2023 Filed Dec 28, 2023 22:00 UTC | CRYO CELL INTERNATIONAL INC CCEL · Entity 7400 | GrantStock Option · Derivative | 10,000 | $5.88 Strike: $5.88 | $58,800.00 |
DisclosureSEC source: 0001209191-23-059919 · doc4.xml · derivative · entry 5 TAYMANS JILL M · CIK 0001261283 · VP Finance, CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2028-12-22 F3 · derivative.exercise_date: Stock options vest 1/3 upon issuance, 1/3 on December 22, 2024 and 1/3 on December 22, 2025. Read SEC document |
| January 13, 2023 Filed Jan 17, 2023 22:00 UTC | CRYO CELL INTERNATIONAL INC CCEL · Entity 7400 | GrantStock Option · Derivative | 20,000 | $4.62 Strike: $4.62 | $92,400.00 |
DisclosureSEC source: 0001209191-23-003547 · doc4.xml · derivative · entry 4 TAYMANS JILL M · CIK 0001261283 · VP Finance, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2028-01-13 F2 · derivative.exercise_date: Stock options fully vest upon issuance. Read SEC document |
| September 23, 2020 Filed Sep 25, 2020 22:27 UTC | CRYO CELL INTERNATIONAL INC CCEL · Entity 7400 | GrantStock Option · Derivative | 7,000 | $8.00 Strike: $8.00 | $56,000.00 |
DisclosureSEC source: 0001209191-20-052134 · doc4.xml · derivative · entry 3 TAYMANS JILL M · CIK 0001261283 · VP Finance, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,000 Underlying: Common Stock · 7,000 shares Expires 2027-09-22 F1 · derivative.exercise_date: Stock options vest at a rate of 1/5 annually commencing on September 23, 2021. Read SEC document |
| February 01, 2017 Filed Feb 6, 2017 21:16 UTC | CRYO CELL INTERNATIONAL INC CCEL · Entity 7400 | Exercise / conversionStock Option · Derivative | 9,281 | $1.50 Strike: $1.50 | $13,921.50 |
DisclosureSEC source: 0000899243-17-002847 · doc4.xml · derivative · entry 2 TAYMANS JILL M · CIK 0001261283 · VP, Finance, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,281 shares Expires 2017-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: 1/3 vest one year from date of grant, 1/3 vest two years from date of grant, 1/3 vest three years from date of grant Read SEC document |
| February 01, 2017 Filed Feb 6, 2017 21:16 UTC | CRYO CELL INTERNATIONAL INC CCEL · Entity 7400 | Exercise / conversionCommon Stock | 9,281 | $1.50 | $13,921.50 |
DisclosureSEC source: 0000899243-17-002847 · doc4.xml · nonDerivative · entry 1 TAYMANS JILL M · CIK 0001261283 · VP, Finance, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,396 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 02, 2016 Filed Feb 6, 2017 21:16 UTC | CRYO CELL INTERNATIONAL INC CCEL · Entity 7400 | GrantStock Option · Derivative | 7,500 | $3.10 Strike: $3.10 | $23,250.00 |
DisclosureSEC source: 0000899243-17-002847 · doc4.xml · derivative · entry 3 TAYMANS JILL M · CIK 0001261283 · VP, Finance, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 7,500 shares Expires 2026-06-02 F1 · derivative.exercise_date: 1/3 vest one year from date of grant, 1/3 vest two years from date of grant, 1/3 vest three years from date of grant Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.